Leslie Meltzer - 26 Aug 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Research and Development
Signature
/s/ David Watson, attorney-in-fact for Leslie Meltzer
Issuer symbol
APLS
Transactions as of
26 Aug 2025
Net transactions value
$0
Form type
4
Filing time
02 Sep 2025, 10:13:46 UTC
Next filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MELTZER LESLIE Chief Research and Development C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Leslie Meltzer 02 Sep 2025 0002084030

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +61,804 $0.000000 61,804 26 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $0 +92,592 $0.000000 92,592 26 Aug 2025 Common Stock 92,592 $16.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock unit was granted on August 26, 2025. The restricted stock unit will vest 25% annually over four years from grant date, subject to her continued service as an officer, or upon later termination of her service.
F2 This represents a stock option award granted August 26, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.